Profile
Michael Chen is associated with Nuclera Nucleics Ltd.
as the founder.
He holds the title of Chief Executive Officer & Director since 2013.
Michael Chen active positions
Companies | Position | Start |
---|---|---|
Nuclera Nucleics Ltd.
Nuclera Nucleics Ltd. BiotechnologyHealth Technology Nuclera Nucleics Ltd. is a British company that specializes in making biology accessible through desktop enzymatic protein and gene synthesis. The company was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. Nuclera has since grown to fifty-seven employees across two continents and is headquartered in Cambridge, UK. The company's vision is to make biology accessible to everyone through desktop bioprinting, which empowers researchers and scientists to take control of biology through streamlined access to a next-day supply of proteins and genes. Nuclera's desktop bioprinter is enabled by three exciting technologies protected by 45+ patents: enzymatic protein synthesis, enzymatic gene synthesis, and digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform creates an unprecedented one-stop-shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers. Michael Chen has been the CEO since 2013. | Founder | 2012-12-31 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Nuclera Nucleics Ltd.
Nuclera Nucleics Ltd. BiotechnologyHealth Technology Nuclera Nucleics Ltd. is a British company that specializes in making biology accessible through desktop enzymatic protein and gene synthesis. The company was founded in 2013 by four PhD students at the University of Cambridge who were frustrated by the inaccessibility of biology. Nuclera has since grown to fifty-seven employees across two continents and is headquartered in Cambridge, UK. The company's vision is to make biology accessible to everyone through desktop bioprinting, which empowers researchers and scientists to take control of biology through streamlined access to a next-day supply of proteins and genes. Nuclera's desktop bioprinter is enabled by three exciting technologies protected by 45+ patents: enzymatic protein synthesis, enzymatic gene synthesis, and digital microfluidics. The combination of these technologies in a deployable desktop bioprinting platform creates an unprecedented one-stop-shop ecosystem that enables Nuclera to provide consistent biological workflows, products, and information to its customers. Michael Chen has been the CEO since 2013. | Health Technology |
- Stock Market
- Insiders
- Michael Chen